Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 140 entries
Sorted by: Best Match Show Resources per page
A knowledge translation challenge: clinical use of quality of life data from cancer clinical trials

Educational trials

Brundage M, Foley K.
GSID: 3PFMk_gHFjQJ
M Brundage, B Bass, R Jolie, K Foley - Quality of Life Research, 2011 - Springer

… physician attitudes toward HRQL, and to explore whether educational interventions would be useful in enhancing HRQL knowledge … an oncology setting, given previous illustrations of considerable variation in how HRQL data are presented in cancer clinical trials [11–13]....

Cite
Brundage, M., Bass, B., Jolie, R., & Foley, K. (2011). A knowledge translation challenge: clinical use of quality of life data from cancer clinical trials. Quality of Life Research, 20(7), 979-985.
Brundage, Michael, et al. "A knowledge translation challenge: clinical use of quality of life data from cancer clinical trials." Quality of Life Research 20.7 (2011): 979-985.
Copy Download .nbib Format: MLA
Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Eapen LJ, Jones E, Kassouf W, Lambert C, Morgan SC, Moussa M, Nam R, Parliament M, Russell L, Saad F, Siemens DR, Souhami L, Szumacher E, Tyldesley S, Xu Y, Zbieranowski I, Breau RH, Belanger E, Black P, Estey E, Bowan J, Bora B, Brundage M, Chung P, Fleshner N, Evans A, Bauman G, Izawa J, Davidson C, Brimo F.
PMID: 27217852
Can Urol Assoc J. 2016 Mar-Apr;10(3):90-4. doi: 10.5489/cuaj.3456.

INTRODUCTION: We aimed to enumerate the rate of pelvic recurrence following radical cystectomy at university-affiliated hospitals in Canada.METHODS: Canadian, university-affiliated hospitals were invited to participate. They were asked to identify the first 10 consecutive patients undergoing radical cystectomy starting...

Cite
Eapen LJ, Jones E, Kassouf W, et al. Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. Can Urol Assoc J. 2016;10(3):90-4doi: 10.5489/cuaj.3456.
Eapen, L. J., Jones, E., Kassouf, W., Lambert, C., Morgan, S. C., Moussa, M., Nam, R., Parliament, M., Russell, L., Saad, F., Siemens, D. R., Souhami, L., Szumacher, E., Tyldesley, S., Xu, Y., Zbieranowski, I., Breau, R. H., Belanger, E., Black, P., Estey, E., Bowan, J., Bora, B., Brundage, M., Chung, P., Fleshner, N., Evans, A., Bauman, G., Izawa, J., Davidson, C., & Brimo, F. (2016). Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 10(3), 90-4. https://doi.org/10.5489/cuaj.3456
Eapen, Libni J, et al. "Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 10,3 (2016): 90-4. doi: https://doi.org/10.5489/cuaj.3456
Eapen LJ, Jones E, Kassouf W, Lambert C, Morgan SC, Moussa M, Nam R, Parliament M, Russell L, Saad F, Siemens DR, Souhami L, Szumacher E, Tyldesley S, Xu Y, Zbieranowski I, Breau RH, Belanger E, Black P, Estey E, Bowan J, Bora B, Brundage M, Chung P, Fleshner N, Evans A, Bauman G, Izawa J, Davidson C, Brimo F. Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. Can Urol Assoc J. 2016 Mar-Apr;10(3):90-4. doi: 10.5489/cuaj.3456. PMID: 27217852; PMCID: PMC4840007.
Copy Download .nbib Format: NLM
Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol.

BMJ open

Ahmed K, Kyte D, Keeley T, Efficace F, Armes J, Brown JM, Calman L, Copland C, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor R, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M.
PMID: 27655263
BMJ Open. 2016 Sep 21;6(9):e012863. doi: 10.1136/bmjopen-2016-012863.

INTRODUCTION: Emerging evidence suggests that patient-reported outcome (PRO)-specific information may be omitted in trial protocols and that PRO results are poorly reported, limiting the use of PRO data to inform cancer care. This study aims to evaluate the standards...

Cite
Ahmed K, Kyte D, Keeley T, et al. Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol. BMJ Open. 2016;6(9):e012863doi: 10.1136/bmjopen-2016-012863.
Ahmed, K., Kyte, D., Keeley, T., Efficace, F., Armes, J., Brown, J. M., Calman, L., Copland, C., Gavin, A., Glaser, A., Greenfield, D. M., Lanceley, A., Taylor, R., Velikova, G., Brundage, M., Mercieca-Bebber, R., King, M. T., & Calvert, M. (2016). Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol. BMJ open, 6(9), e012863. https://doi.org/10.1136/bmjopen-2016-012863
Ahmed, Khaled, et al. "Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol." BMJ open vol. 6,9 (2016): e012863. doi: https://doi.org/10.1136/bmjopen-2016-012863
Ahmed K, Kyte D, Keeley T, Efficace F, Armes J, Brown JM, Calman L, Copland C, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor R, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M. Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol. BMJ Open. 2016 Sep 21;6(9):e012863. doi: 10.1136/bmjopen-2016-012863. PMID: 27655263; PMCID: PMC5051436.
Copy Download .nbib Format: NLM
Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study.

Clinical & translational immunology

Johnson KH, Webb CH, Schmeling DO, Brundage RC, Balfour HH.
PMID: 27350880
Clin Transl Immunology. 2016 May 13;5(5):e81. doi: 10.1038/cti.2016.28. eCollection 2016 May.

Characterizing Epstein-Barr virus (EBV) dynamics in asymptomatic immunocompetent persons provides a baseline for defining quantitative thresholds associated with EBV disease. Studying latent membrane protein (LMP)-1 sequence variation over time could establish the rates of reactivation and superinfection, and also...

Cite
Johnson KH, Webb CH, Schmeling DO, et al. Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study. Clin Transl Immunology. 2016;5(5):e81doi: 10.1038/cti.2016.28.
Johnson, K. H., Webb, C. H., Schmeling, D. O., Brundage, R. C., & Balfour, H. H. (2016). Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study. Clinical & translational immunology, 5(5), e81. https://doi.org/10.1038/cti.2016.28
Johnson, Kristin H, et al. "Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study." Clinical & translational immunology vol. 5,5 (2016): e81. doi: https://doi.org/10.1038/cti.2016.28
Johnson KH, Webb CH, Schmeling DO, Brundage RC, Balfour HH. Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study. Clin Transl Immunology. 2016 May 13;5(5):e81. doi: 10.1038/cti.2016.28. eCollection 2016 May. PMID: 27350880; PMCID: PMC4910122.
Copy Download .nbib Format: NLM
Practical issues in assisting shared decision-making.

Health expectations : an international journal of public participation in health care and health policy

Feldman-Stewart D, Brundage MD, McConnell BA, MacKillop WJ.
PMID: 11281911
Health Expect. 2000 Mar;3(1):46-54. doi: 10.1046/j.1369-6513.2000.00082.x.

To facilitate treatment decision-making, one aims to provide information, present it in a way that makes it as easy as possible to understand, and to help the decision-maker through the cognitive processes that result in a treatment decision. Decision...

Cite
Feldman-Stewart D, Brundage MD, McConnell BA, et al. Practical issues in assisting shared decision-making. Health Expect. 2000;3(1):46-54doi: 10.1046/j.1369-6513.2000.00082.x.
Feldman-Stewart, D., Brundage, M. D., McConnell, B. A., & MacKillop, W. J. (2000). Practical issues in assisting shared decision-making. Health expectations : an international journal of public participation in health care and health policy, 3(1), 46-54. https://doi.org/10.1046/j.1369-6513.2000.00082.x
Feldman-Stewart, Deb, et al. "Practical issues in assisting shared decision-making." Health expectations : an international journal of public participation in health care and health policy vol. 3,1 (2000): 46-54. doi: https://doi.org/10.1046/j.1369-6513.2000.00082.x
Feldman-Stewart D, Brundage MD, McConnell BA, MacKillop WJ. Practical issues in assisting shared decision-making. Health Expect. 2000 Mar;3(1):46-54. doi: 10.1046/j.1369-6513.2000.00082.x. PMID: 11281911; PMCID: PMC5081085.
Copy Download .nbib Format: NLM
Some Implications Afforded by Mortality and Morbidity Statistics.

American journal of public health and the nation's health

Brundage DK.
PMID: 18014591
Am J Public Health Nations Health. 1937 Mar;27(3):261-6. doi: 10.2105/ajph.27.3.261.

No abstract available.

Cite
Brundage DK. Some Implications Afforded by Mortality and Morbidity Statistics. Am J Public Health Nations Health. 1937;27(3):261-6doi: 10.2105/ajph.27.3.261.
Brundage, D. K. (1937). Some Implications Afforded by Mortality and Morbidity Statistics. American journal of public health and the nation's health, 27(3), 261-6. https://doi.org/10.2105/ajph.27.3.261
Brundage, D K. "Some Implications Afforded by Mortality and Morbidity Statistics." American journal of public health and the nation's health vol. 27,3 (1937): 261-6. doi: https://doi.org/10.2105/ajph.27.3.261
Brundage DK. Some Implications Afforded by Mortality and Morbidity Statistics. Am J Public Health Nations Health. 1937 Mar;27(3):261-6. doi: 10.2105/ajph.27.3.261. PMID: 18014591; PMCID: PMC1563056.
Copy Download .nbib Format: NLM
Phonon-induced relaxation in excited optical states of trivalent neptunium in LaCl3.

Optics letters

Hessler JP, Brundage RT, Hegarty J, Yen WM.
PMID: 19693224
Opt Lett. 1980 Aug 01;5(8):348. doi: 10.1364/ol.5.000348.

No abstract available.

Cite
Hessler JP, Brundage RT, Hegarty J, et al. Phonon-induced relaxation in excited optical states of trivalent neptunium in LaCl3. Opt Lett. 1980;5(8):348doi: 10.1364/ol.5.000348.
Hessler, J. P., Brundage, R. T., Hegarty, J., & Yen, W. M. (1980). Phonon-induced relaxation in excited optical states of trivalent neptunium in LaCl3. Optics letters, 5(8), 348. https://doi.org/10.1364/ol.5.000348
Hessler, J P, et al. "Phonon-induced relaxation in excited optical states of trivalent neptunium in LaCl3." Optics letters vol. 5,8 (1980): 348. doi: https://doi.org/10.1364/ol.5.000348
Hessler JP, Brundage RT, Hegarty J, Yen WM. Phonon-induced relaxation in excited optical states of trivalent neptunium in LaCl3. Opt Lett. 1980 Aug 01;5(8):348. doi: 10.1364/ol.5.000348. PMID: 19693224.
Copy Download .nbib Format: NLM
NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an illustrative study in a palliative setting.

Expert review of pharmacoeconomics & outcomes research

Brundage M, Bezjak A, Tu D, Palmer M, Pater J.
PMID: 20528376
Expert Rev Pharmacoecon Outcomes Res. 2008 Jun;8(3):243-53. doi: 10.1586/14737167.8.3.243.

In this article we briefly review the experience of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) with respect to the assessment of patient reported outcomes in clinical trials, and illustrate issues important to assessing symptom...

Cite
Brundage M, Bezjak A, Tu D, et al. NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an illustrative study in a palliative setting. Expert Rev Pharmacoecon Outcomes Res. 2008;8(3):243-53doi: 10.1586/14737167.8.3.243.
Brundage, M., Bezjak, A., Tu, D., Palmer, M., & Pater, J. (2008). NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an illustrative study in a palliative setting. Expert review of pharmacoeconomics & outcomes research, 8(3), 243-53. https://doi.org/10.1586/14737167.8.3.243
Brundage, Michael, et al. "NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an illustrative study in a palliative setting." Expert review of pharmacoeconomics & outcomes research vol. 8,3 (2008): 243-53. doi: https://doi.org/10.1586/14737167.8.3.243
Brundage M, Bezjak A, Tu D, Palmer M, Pater J. NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an illustrative study in a palliative setting. Expert Rev Pharmacoecon Outcomes Res. 2008 Jun;8(3):243-53. doi: 10.1586/14737167.8.3.243. PMID: 20528376.
Copy Download .nbib Format: NLM
Why did many more diamond miners than gold miners die in South Africa during the 1918 influenza pandemic?.

International health

Shanks GD, Brundage J, Frean J.
PMID: 24037050
Int Health. 2010 Mar;2(1):47-51. doi: 10.1016/j.inhe.2009.12.001.

The very large difference in mortality rates between Kimberley diamond miners and Witwatersrand gold miners during the 1918 influenza pandemic has never been explained. We examined extant epidemiological records from South African mining operations and other related activities to...

Cite
Shanks GD, Brundage J, Frean J. Why did many more diamond miners than gold miners die in South Africa during the 1918 influenza pandemic?. Int Health. 2010;2(1):47-51doi: 10.1016/j.inhe.2009.12.001.
Shanks, G. D., Brundage, J., & Frean, J. (2010). Why did many more diamond miners than gold miners die in South Africa during the 1918 influenza pandemic?. International health, 2(1), 47-51. https://doi.org/10.1016/j.inhe.2009.12.001
Shanks, G Dennis, et al. "Why did many more diamond miners than gold miners die in South Africa during the 1918 influenza pandemic?." International health vol. 2,1 (2010): 47-51. doi: https://doi.org/10.1016/j.inhe.2009.12.001
Shanks GD, Brundage J, Frean J. Why did many more diamond miners than gold miners die in South Africa during the 1918 influenza pandemic?. Int Health. 2010 Mar;2(1):47-51. doi: 10.1016/j.inhe.2009.12.001. PMID: 24037050; PMCID: PMC7314043.
Copy Download .nbib Format: NLM
Homogeneous linewidth of the 5D0-7F0 transition of trivalent europium in a fluorophosphate glass.

Physical review. B, Condensed matter

Brundage RT, Reyerson CS.
PMID: 9982460
Phys Rev B Condens Matter. 1996 Apr 01;53(14):R8821-R8823. doi: 10.1103/physrevb.53.r8821.

No abstract available.

Cite
Brundage RT, Reyerson CS. Homogeneous linewidth of the 5D0-7F0 transition of trivalent europium in a fluorophosphate glass. Phys Rev B Condens Matter. 1996;53(14):R8821-R8823doi: 10.1103/physrevb.53.r8821.
Brundage, R. T., & Reyerson, C. S. (1996). Homogeneous linewidth of the 5D0-7F0 transition of trivalent europium in a fluorophosphate glass. Physical review. B, Condensed matter, 53(14), R8821-R8823. https://doi.org/10.1103/physrevb.53.r8821
Brundage, and Reyerson. "Homogeneous linewidth of the 5D0-7F0 transition of trivalent europium in a fluorophosphate glass." Physical review. B, Condensed matter vol. 53,14 (1996): R8821-R8823. doi: https://doi.org/10.1103/physrevb.53.r8821
Brundage RT, Reyerson CS. Homogeneous linewidth of the 5D0-7F0 transition of trivalent europium in a fluorophosphate glass. Phys Rev B Condens Matter. 1996 Apr 01;53(14):R8821-R8823. doi: 10.1103/physrevb.53.r8821. PMID: 9982460.
Copy Download .nbib Format: NLM
Prostate cancer patients' experience and preferences for acquiring information early in their care.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Feldman-Stewart D, Tong C, Brundage M, Bender J, Robinson J.
PMID: 29405903
Can Urol Assoc J. 2018 May;12(5):E219-E225. doi: 10.5489/cuaj.4754. Epub 2018 Feb 06.

INTRODUCTION: Prostate cancer patients' information needs are well-described, but little is known about their preferred sources and media for obtaining information. We sought to determine prostate cancer patients' experiences and preferences for acquiring information after diagnosis, a time of...

Cite
Feldman-Stewart D, Tong C, Brundage M, et al. Prostate cancer patients' experience and preferences for acquiring information early in their care. Can Urol Assoc J. 2018;12(5):E219-E225doi: 10.5489/cuaj.4754.
Feldman-Stewart, D., Tong, C., Brundage, M., Bender, J., & Robinson, J. (2018). Prostate cancer patients' experience and preferences for acquiring information early in their care. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 12(5), E219-E225. https://doi.org/10.5489/cuaj.4754
Feldman-Stewart, Deb, et al. "Prostate cancer patients' experience and preferences for acquiring information early in their care." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 12,5 (2018): E219-E225. doi: https://doi.org/10.5489/cuaj.4754
Feldman-Stewart D, Tong C, Brundage M, Bender J, Robinson J. Prostate cancer patients' experience and preferences for acquiring information early in their care. Can Urol Assoc J. 2018 May;12(5):E219-E225. doi: 10.5489/cuaj.4754. Epub 2018 Feb 06. PMID: 29405903; PMCID: PMC5966933.
Copy Download .nbib Format: NLM
The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature.

JAMA oncology

Raphael MJ, Robinson A, Booth CM, O'Donnell J, Palmer M, Eisenhauer E, Brundage M.
PMID: 31556921
JAMA Oncol. 2019 Dec 01;5(12):1779-1789. doi: 10.1001/jamaoncol.2019.3338.

IMPORTANCE: It is unclear whether patients with advanced cancer value surrogate end points, particularly progression-free survival (PFS). Despite this uncertainty, surrogate end points form the basis of regulatory approval for the majority of new cancer treatments.OBJECTIVE: To summarize and...

Cite
Raphael MJ, Robinson A, Booth CM, et al. The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature. JAMA Oncol. 2019;5(12):1779-1789doi: 10.1001/jamaoncol.2019.3338.
Raphael, M. J., Robinson, A., Booth, C. M., O'Donnell, J., Palmer, M., Eisenhauer, E., & Brundage, M. (2019). The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature. JAMA oncology, 5(12), 1779-1789. https://doi.org/10.1001/jamaoncol.2019.3338
Raphael, Michael J, et al. "The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature." JAMA oncology vol. 5,12 (2019): 1779-1789. doi: https://doi.org/10.1001/jamaoncol.2019.3338
Raphael MJ, Robinson A, Booth CM, O'Donnell J, Palmer M, Eisenhauer E, Brundage M. The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature. JAMA Oncol. 2019 Dec 01;5(12):1779-1789. doi: 10.1001/jamaoncol.2019.3338. PMID: 31556921.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 140 entries